Nootropics

Vinpocetine

Evidence: moderate_human

Mechanism of Action

Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.

Dosing Protocol

Standard: 5-20 mg 2-3 times daily (15-60 mg/day total)

Maintenance: 5-10 mg 2-3 times daily

Administration: oral

Timing: With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).

Duration: Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.

Notes

A cerebral blood flow enhancer with a distinct mechanism from ginkgo (PDE1 inhibition vs. PAF antagonism). The Cochrane Review (Szatmari & Whitehouse 2003) found the evidence insufficient to recommend for dementia due to limited trial quality, but individual trials show promising results for cerebrovascular cognitive impairment. The FDA's 2019 warning specifically concerned reproductive toxicity, not general safety. The short half-life necessitates multiple daily doses. Best suited for conditions involving cerebral hypoperfusion. European clinical use for post-stroke cognitive recovery is well-established. Must be taken with food for adequate absorption.

Stacking

  • Ginkgo Biloba
  • Alpha-GPC
  • Piracetam
  • Phosphatidylserine

Interactions

  • Anticoagulants/Antiplatelets [MEDIUM] — May potentiate anticoagulant effects via inhibition of platelet aggregation and red blood cell aggregation
  • Antihypertensives [LOW] — Additive hypotensive effects possible via vasodilation
  • CYP3A4 inhibitors [LOW] — Vinpocetine is partially metabolized by CYP3A4; inhibitors may increase plasma levels

Contraindications

  • Severe hepatic impairment
  • Pregnancy and lactation (FDA issued warning in 2019)
  • Severe cardiac arrhythmias
  • Recent hemorrhagic stroke

Side Effects

  • Flushing
  • GI distress
  • Headache
  • Dizziness
  • Transient hypotension
  • Sleep disturbance

Key Papers

  • 10.1186/s12868-023-00790-8
  • 10.1016/S1734-1140(11)70574-6
  • 10.1002/14651858.CD003119

Source Quality

Pharmaceutical-grade available in Europe and Asia (Cavinton by Gedeon Richter is the gold standard). Available as a dietary supplement in the US, though FDA issued concerns about its safety in 2019, particularly for pregnant women. Ensure >98% purity by HPLC. Capsule form preferred; some evidence that time-release formulations improve the short half-life issue.

Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should Vinpocetine Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds